

OncoTherapy Science, Inc.

March 17, 2016

The Phase I clinical study of OTS167, MELK specific inhibitor, in Australia

OncoTherapy Science, Inc. (President & CEO: Masaharu Mori; hereinafter, "OncoTherapy") announces that Phase I clinical study of OTS167, MELK specific inhibitor, in Australia for the evaluation of bioavailability which was press-released on January 5, 2016 have been completed with favorable results.

Study results

During January to February 2016, eleven healthy adults were enrolled in this trial, and administrated the adequate dose of OTS167 orally. No clinical adverse event was observed, and unexpected serious adverse drug reaction was not reported either. Additionally, good bioavailability was confirmed from all subjects administrated OTS167.

The safety, efficacy and pharmacokinetic profiles of OTS167 administered intravenously for solid cancer patients have been evaluated in the ongoing Phase I clinical study being held at University of Chicago. On top of the foregoing clinical studies Phase I/II clinical study for Acute Myeloid Leukemia (AML) have commenced at University of Chicago.

The results from this Phase I study in Australia would encourage further clinical development of oral OTS167 formulation.